Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,198.64 -766.26 (-1.20%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
Recursion Pharmaceuticals, Inc. (RXRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 7.84 |
| Open | 7.86 |
| Bid | 8.08 x 400 |
| Ask | 8.14 x 1200 |
| Day's range | 7.68 - 8.14 |
| 52-week range | 4.54 - 16.75 |
| Volume | |
| Avg. volume | 6,332,733 |
| Market cap | 1.929B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
ZacksRecursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals (RXRX) closed at $7.84 in the latest trading session, marking a -1.26% move from the prior day.
ZacksRecursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed at $7.47 in the latest trading session, marking a -1.32% move from the prior day.
GlobeNewswireRecursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors Photo of Najat Khan, Ph.D. Najat Khan, Ph.D. SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief
© 2024 Yahoo. All rights reserved.